Qlik Technologies, Inc. (QLIK), a provider of user-driven business intelligence solutions, was downgraded by Morgan Stanley (MS) analysts to ‘Equal-Weight’ from an ‘Overweight’ rating Monday. The firm also cut its 12-month base case estimate on the name to $29 from $34.
On valuation-measures, shares of Qlik Technologies have a forward P/E and P/E to growth ratio of 66.08 and 4.12, respectively. T-12 profit margin is (4.88%) while EPS registers at ($0.28). The company has a market cap of $2.32B and a median Wall Street price target of $31.50 with a high target of $38.00.
On trading-measure, QLIK has a beta of 1.95 and a short float of 10.40%. In the past 52 weeks, shares of Radnor, Pennsylvania-based company have traded between a low of $20.17 and a high of $35.20 with the 50-day MA and 200-day MA located at $27.84 and $24.83 levels, respectively.
QLIK currently prints a one year loss of about 21% and a year-to-date return of around 1.43%.
Shares of Tekmira Pharmaceuticals Corp. (TKMR) plunged 16% in early trade Monday after the company was downgraded to ‘Market Perform’ from ‘Outperform’ at Leerink Swann. The firm said it believes that “a scenario reflecting significant TKM-EBOLA profits is now baked into the stock”. The firm raised the name’s price target to $30 from $25 despite the downgraded outlook.
Tekmira Pharmaceuticals, which is working to develop an Ebola vaccine, has received FDA authorization to use its TKM-EBOLA treatement under an expanded access protocol in individuals that are already infected with Ebola virus.
TKMR, currently valued at $652.79M, has a median Wall Street price target of $27.53 with a high target of $28.44. Approximately 11,064,958 shares have already changed hands, compared to the stock’s average daily volume of 4,521,130.
Tekmira shares are up 178% year-over-year and 211.29% year-to-date.
PTC Therapeutics, Inc. (PTCT) shares are falling sharply, down more than 11% to $40.72 on Monday, after analysts at Cowen downgraded the stock to ‘Market perform” from ‘Outperform’.
PTC Therapeutics, currently valued at $1.19B, has a median Wall Street price target of $55.00 with a high target of $75.00. Approximately 224,449 shares have already changed hands, compared to the stock’s average daily volume of 295,727.
In the past 52 weeks, shares of South Plainfield, New Jersey-based biopharmaceutical company have traded between a low of $13.15 and a high of $47.20 with the 50-day MA and 200-day MA located at $36.33 and $26.92 levels, respectively. Additionally, shares of PTCT trade at a price/book ratio of 6.01 and have a Relative Strength Index (RSI) and MACD indicator of 55.28 and +1.13, respectively.
PTCT currently prints a one year return of about 136.36% and a year-to-date return of around 170.06%.
Shares of Xoom Corporation (XOOM) were downgraded to an ‘Underweight’ rating from ‘Equal-weight’ by Evercore on Monday. The firm also cut the name’s 12-month base case estimate to $10 from $15.
On valuation-measures, shares of Xoom Corporation have a trailing-12 and forward P/E of 209.51 and 48.56, respectively. P/E to growth ratio is 3.45, while t-12 profit margin is 2.90%. EPS registers at $0.10. The company has a market cap of $816.08M and a median Wall Street price target of $33.00 with a high target of $40.00.
On trading-measure, XOOM has a beta of 2.85 and a short float of 9.20%. In the past 52 weeks, shares of the media solutions provider have traded between a low of $16.90 and a high of $36.07 with its 50-day MA and 200-day MA located at $22.76 and $22.53 levels, respectively.
XOOM currently prints a one year loss of about 28.14% and a year-to-date loss of around 16.77%.